

An automated animal fluency scorer: development and validation across languages

Jeremias Inchauspe^{1,2}, Franco Ferrante^{1,2,3}, Gonzalo Perez^{1,2,3}, Alejandro Sosa-Welford^{1,2}, Lucas Sterpin^{1,2}, Nicolas Pelella¹, Matias Caccia¹, Celeste Moyano⁴, Alejandra Peláez⁵, Deissy Garcia⁵, Jimena Gomez⁶, Paula Arellano^{2,4}, Luis Montiel⁷, Luciano del Corro¹, Agustina Birba^{1,8}, Agustin Ibañez^{1,9,10}, Lucia Amoruso^{1,11}, Adolfo M. Garcia^{1,10,12}



¹ CNC, UdeSA, Argentina; ² CONICET, Argentina; ³ FIUBA, Argentina; ⁴ IIPBA, FFyH, UCCuyo, Argentina; ⁵ Hospital Universitario San Ignacio, Colombia; ⁶ Instituto Nacional de Ciencias Médicas y Nutrición Mexico; ⁷ National Institute of Neurology and Neurosurgery, Mexico; ⁸ Universidad de La Laguna, Spain; ⁹ BrainLat, Chile; ¹⁰ GBHI, USA; ¹¹ BCBL, Spain; ¹² Universidad de Santiago de Chile, Chile

Introduction

Animal fluency tasks are core to dementia screening, diagnosis and monitoring¹. Valid responses reveal deficits in Alzheimer's disease and behavioral variant frontotemporal dementia², tracking decline and predicting clinical progression^{3,4}. However, standard scoring relies on inconsistent criteria and fallible manual work from experts unequally available across regions, compromising reliability, and scalability^{2,5}. Here, we validate TELL's digital fluency scorer, an AI tool automating end-to-end acquisition, preprocessing, scoring, and reporting.

Methods

Results



Conclusions

- TELL's fluency scorer consistently matched expert scoring in semi- and fully automated workflows.
- Validation in English and Spanish covers two of the world's most widely spoken languages, both globally and among people living with dementia.
- This shows LLMs can advance efficiency, scalability, and equity in digital health.

References

1. Villalobos, D. et al. *Neuropsychology Review* 33, 733–764 (2023).
2. Ferrante, F. J. et al. *Alzheimer's & Dementia* 20, 925–940 (2024).
3. Folia, V. et al. *Journal of the International Neuropsychological Society* 29, 450–458 (2023).
4. van den Berg, R. L. et al. *Alzheimer's & Dementia* 17, e70063 (2025).
5. Thompson, L. I. et al. *Alzheimer's & Dementia* 21, e70966 (2025).

Interested in this research?

Jeremias Inchauspe
Doctoral Researcher
San Andres University
CONICET
jinchauspe@udesa.edu.ar



Fogarty International Center, NIH/NIA: R01 AG057234, R01 AG075775, R01 AG21051, R01 AG083799, 2P01AG019724, CARDS-NIH; Alzheimer's Association: SG-20-725707; Rainwater Charitable Foundation/Bluefield Project; GBHI; ANID/FONDECYT Regular: 1250091, 1210176, 1220995, 1250317; ANID/PIA/ANILLOS: ACT210096; JPI JPND-Care: DISCeRN 2025; ANID/FONDEF: ID2010152; ANID/FONDAP: 15150012; Wellcome Trust: 335293/Z/25/Z; Wellcome Leap CARE: CARE-2025-0883490149; Horizon Europe/MSCA: CtiCBrain 101236426, DOI 10.3030/101236426; ANPCyT: 01-PIC-TE-2022-05-00103; and grant PID2024-160664OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the ESF+. Attendance at this conference was supported by an AAIC 2026 Conference Fellowship.

Contact